SCHEMBL4892565

SCHEMBL4892565

CCOC(=O)C1CCN(CC(=O)Nc2ccc(C)c(Nc3nccc(-c4ccncc4)n3)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 15/20 0.54
PDGFRB P09619 7/20 0.54
KIT P10721 6/20 0.54
LMNA P02545 3/20 0.51
KDM4E B2RXH2 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
BCR P11274 11/20 0.49
PDGFRA P16234 5/20 0.48
TP53 P04637 1/20 0.47
EGFR P00533 2/20 0.47
PLK4 O00444 1/20 0.47
DDX3X O00571 1/20 0.47
GAK O14976 1/20 0.47
SLC22A2 O15244 1/20 0.47
MAPK13 O15264 1/20 0.47
CA12 O43570 1/20 0.47
SLC22A3 O75751 1/20 0.47
ABCB11 O95342 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904891 0.92 ABL1 (0.61) ABL1PDGFRBKITLMNABCR
SCHEMBL4903667 0.90 PTK2 (0.53) LMNAKDM4ESMN1; SMN2PTK2
SCHEMBL4900835 0.89 LMNA (0.50) ABL1PDGFRBLMNAKDM4ESMN1; SMN2
SCHEMBL4893382 0.88 LMNA (0.50) ABL1PDGFRBKITLMNAKDM4E
SCHEMBL4901647 0.88 ALDH1A1 (0.54) ABL1PDGFRBKITLMNAKDM4E
SCHEMBL4903153 0.85 ABL1 (0.63) ABL1PDGFRBKITLMNABCR
SCHEMBL4900880 0.84 ABL1 (0.54) ABL1PDGFRBKITLMNABCR
SCHEMBL4901373 0.82 ABL1 (0.59) ABL1PDGFRBLMNAKDM4EBCR
SCHEMBL4905299 0.80 SMN1; SMN2 (0.56) ABL1PDGFRBKITLMNASMN1; SMN2
SCHEMBL4897520 0.80 ABL1 (0.67) ABL1PDGFRBKITLMNABCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885PDGFRB 299/4885KIT 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.